Despite fears that the US federal regulator would block pharma giant Actavis Inc’s $8.5bn acquisition of Dublin-based Warner Chilcott the deal, which saw Latham & Watkins and Matheson advise Actavis opposite Davis Polk & Wardwell and Arthur Cox, has closed this month.
The Federal Trade Commission at the end of September settled charges that the deal would be anticompetitive, after Actavis agreed to sell its rights and assets related to three oral contraceptives and an osteoporosis treatment.
Your limit of 1 article in 30 days is up. Please login for full access or subscribe.
Corporate users - click here for simple access (no password needed).
For more information, please contact jasmine.glass@legalbusiness.co.uk
